Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug ResistantAcinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure | Zendy

Yvonne Peijun Zhou | Zendy; Nathalie Grace Sy Chua | Zendy; Maciej Piotr Chlebicki | Zendy; Winnie Hui Ling Lee | Zendy; Andrea LayHoon Kwa | Zendy

Open Access

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug ResistantAcinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Author(s) -

Yvonne Peijun Zhou,

Nathalie Grace Sy Chua,

Maciej Piotr Chlebicki,

Winnie Hui Ling Lee,

Andrea LayHoon Kwa

Publication year - 2014

Publication title -

case reports in infectious diseases

Language(s) - English

Resource type - Journals

eISSN - 2090-6625

pISSN - 2090-6633

DOI - 10.1155/2014/573279

Subject(s) - medicine , polymyxin , polymyxin b , drug , adverse effect , pharmacokinetics , dosing , antibiotics , acinetobacter baumannii , intensive care medicine , end stage renal failure , pharmacology , microbiology and biotechnology , dialysis , pseudomonas aeruginosa , genetics , bacteria , biology

Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research